{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:24:21Z","timestamp":1784921061481,"version":"3.55.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Diabetic kidney disease (DKD) is a health burden of rising importance. Slowing progression to end stage kidney disease is the main goal of drug treatment. The aim of this analysis is to compare drug treatments of DKD by means of a systemic review and a network meta-analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We searched Medline, CENTRAL and clinicaltrials.gov for randomized, controlled studies including adults with DKD treated with the following drugs of interest: single angiotensin-converting-enzyme-inhibitor or angiotensin-receptor-blocker (single ACEi\/ARB), angiotensin-converting-enzyme-inhibitor and angiotensin-receptor-blocker combination (ACEi+ARB combination), aldosterone antagonists, direct renin inhibitors, non-steroidal mineralocorticoid-receptor-antagonists (nsMRA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i). As primary endpoints, we defined: overall mortality and end-stage kidney disease, as secondary endpoints: renal composite outcome and albuminuria and as safety endpoints: acute kidney injury, hyperkalemia and hypotension. Under the use of a random effects model, we computed the overall effect estimates using the statistic program R4.1 and the corresponding package \u201cnetmeta\u201d. Risk of bias was assessed using the RoB 2 tool and the quality of evidence of each pairwise comparison was rated according to GRADE (Grading of Recommendations Assessment, Development and Evaluation).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Of initial 3489 publications, 38 clinical trials were found eligible, in total including 42346 patients. Concerning the primary endpoints overall mortality and end stage kidney disease, SGLT2i on top of single ACEi\/ARB compared to single ACEi\/ARB was the only intervention significantly reducing the odds of mortality (OR 0.81, 95%CI 0.70\u20130.95) and end-stage kidney disease (OR 0.69, 95%CI 0.54\u20130.88). The indirect comparison of nsMRA vs SGLT2i in our composite endpoint suggests a superiority of SGLT2i (OR 0.60, 95%CI 0.47\u20130.76). Concerning safety endpoints, nsMRA and SGLT2i showed benefits compared to the others.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>As the only drug class, SGLT2i showed in our analysis beneficial effects on top of ACEi\/ARB treatment regarding mortality and end stage kidney disease and by that reconfirmed its position as treatment option for diabetic kidney disease. nsMRA reduced the odds for a combined renal endpoint and did not raise any safety concerns, justifying its application.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0293183","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T17:44:56Z","timestamp":1698947096000},"page":"e0293183","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of diabetic kidney disease. A network meta-analysis"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8769-9752","authenticated-orcid":true,"given":"Fabian","family":"B\u00fcttner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Vollmer","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhejia","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Melk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard M. W.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"issue":"10258","key":"pone.0293183.ref001","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"C Abbafati","year":"2020","journal-title":"The Lancet"},{"issue":"3","key":"pone.0293183.ref002","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jdi.13355","article-title":"Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017","volume":"12","author":"H Li","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"9982","key":"pone.0293183.ref003","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: A network meta-analysis","volume":"385","author":"SC Palmer","year":"2015","journal-title":"The Lancet"},{"key":"pone.0293183.ref004","doi-asserted-by":"crossref","DOI":"10.1159\/000339789","volume-title":"KDIGO clinical practice guidelines for acute kidney injury","author":"A. Khwaja","year":"2012"},{"issue":"20","key":"pone.0293183.ref005","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"LF Fried","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"pone.0293183.ref006","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"V Perkovic","year":"2019","journal-title":"New England journal of medicine"},{"key":"pone.0293183.ref007","doi-asserted-by":"crossref","DOI":"10.1201\/9781003107347","volume-title":"Doing Meta-Analysis with R: A Hands-On Guide","author":"M Harrer","year":"2021"},{"issue":"7","key":"pone.0293183.ref008","volume":"9","author":"G Salanti","year":"2014","journal-title":"Evaluating the Quality of Evidence from a Network Meta- Analysis"},{"key":"pone.0293183.ref009","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPT Higgins","year":"2019","edition":"2"},{"issue":"2","key":"pone.0293183.ref010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta\u2010analysis: concepts and models for multi\u2010arm studies","volume":"3","author":"JPT Higgins","year":"2012","journal-title":"Res Synth Methods"},{"issue":"1","key":"pone.0293183.ref011","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-13-35","article-title":"A graphical tool for locating inconsistency in network meta-analyses","volume":"13","author":"U Krahn","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"September","key":"pone.0293183.ref012","first-page":"1","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"MA Puhan","year":"2014","journal-title":"BMJ (Online)"},{"key":"pone.0293183.ref013","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"R Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"pone.0293183.ref014","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"RA DeFronzo","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"pone.0293183.ref015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"C Wanner","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"pone.0293183.ref016","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jchf.2021.06.017","article-title":"Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure","volume":"9","author":"JJV McMurray","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"11","key":"pone.0293183.ref017","doi-asserted-by":"crossref","first-page":"F1269","DOI":"10.1152\/ajprenal.00543.2015","article-title":"Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron","volume":"310","author":"AT Layton","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"pone.0293183.ref018","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"SC Thomson","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"1","key":"pone.0293183.ref019","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"RA DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"pone.0293183.ref020","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE \u2212\/\u2212 mice fed a western diet","volume":"60","author":"JH Han","year":"2017","journal-title":"Diabetologia"},{"issue":"2","key":"pone.0293183.ref021","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"V Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"pone.0293183.ref022","first-page":"1","article-title":"SGLT2i: beyond the glucose\u2014lowering effect","author":"L Ni","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"pone.0293183.ref023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis","volume":"16","author":"J Menne","year":"2019","journal-title":"PLoS Med"},{"issue":"9568","key":"pone.0293183.ref024","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(07)60242-6","article-title":"Renin-angiotensin system and cardiovascular risk","volume":"369","author":"RE Schmieder","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"pone.0293183.ref025","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function","volume":"24","author":"AH van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"issue":"23","key":"pone.0293183.ref026","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"HH Parving","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0293183.ref027","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifbrotic activity","volume":"71","author":"J Grune","year":"2018","journal-title":"Hypertension"},{"issue":"1","key":"pone.0293183.ref028","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"P Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"issue":"23","key":"pone.0293183.ref029","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"GL Bakris","year":"2020","journal-title":"New England journal of medicine"},{"issue":"24","key":"pone.0293183.ref030","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"B Pitt","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"pone.0293183.ref031","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence","volume":"102","author":"P Rossing","year":"2022","journal-title":"Kidney Int"},{"key":"pone.0293183.ref032","first-page":"974","volume-title":"Kidney international","author":"IH de Boer","year":"2022"},{"key":"pone.0293183.ref033","first-page":"990","volume-title":"Kidney international","author":"P Rossing","year":"2022"},{"issue":"1","key":"pone.0293183.ref034","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy","volume":"7","author":"P Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"7","key":"pone.0293183.ref035","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40262-022-01124-3","article-title":"Dose\u2013Exposure\u2013Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD","volume":"61","author":"SC Goulooze","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"pone.0293183.ref036","first-page":"1","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE)","author":"JB Green","year":"2022","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"pone.0293183.ref037","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL","volume":"65","author":"D De Zeeuw","year":"2004","journal-title":"Kidney Int"},{"issue":"6","key":"pone.0293183.ref038","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MNH.0000000000000541","article-title":"Change in albuminuria as a surrogate endpoint","volume":"28","author":"SW Waijer","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"23","key":"pone.0293183.ref039","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"GL Bakris","year":"2020","journal-title":"New England journal of medicine"},{"issue":"8","key":"pone.0293183.ref040","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/dom.14702","article-title":"Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis","volume":"24","author":"H Cao","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"pone.0293183.ref041","article-title":"Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis","author":"S Ghosal","year":"2022","journal-title":"Diabetes Therapy"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T17:45:34Z","timestamp":1698947134000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293183"}},"subtitle":[],"editor":[{"given":"Licy","family":"Yanes Cardozo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0293183","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]}}}